Stock-Based Compensation: The estimated market value of stock options, warrants and other stock-based compensation given to employees and/or vendors.
Neuphoria Therapeutics Inc. (NEUP) had Stock-Based Compensation of $0.20M for the most recently reported fiscal quarter, ending 2025-12-31.
| Income Statement Financials | |
-- |
|
$1.86M |
|
-- |
|
-- |
|
$4.06M |
|
$-4.06M |
|
$5.89M |
|
$1.83M |
|
$1.83M |
|
$1.86M |
|
$1.86M |
|
$1.86M |
|
$1.86M |
|
$-4.06M |
|
$-3.90M |
|
4.54M |
|
4.54M |
|
$0.41 |
|
$-0.77 |
|
| Balance Sheet Financials | |
$23.39M |
|
-- |
|
$13.21M |
|
$36.60M |
|
$2.59M |
|
-- |
|
$4.31M |
|
$6.90M |
|
$29.70M |
|
$16.49M |
|
$29.70M |
|
5.38M |
|
| Cash Flow Statement Financials | |
$-10.23M |
|
-- |
|
$17.92M |
|
$14.29M |
|
$22.25M |
|
$7.96M |
|
|
Stock-Based Compensation |
$0.20M |
-- |
|
-- |
|
| Fundamental Metrics & Ratios | |
9.04 |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
$-10.23M |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
6.28% |
|
11.30% |
|
5.09% |
|
6.28% |
|
$5.52 |
|
$-2.26 |
|
$-2.26 |
|